Lucid Diagnostics, Inc. (LUCD)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Lucid Diagnostics, Inc. (LUCD)
Company Performance

Current Price

as of Oct 16, 2024

$0.81

P/E Ratio

N/A

Market Cap

$43.73M

Description

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryMedical Specialties
  • TickerLUCD
  • Price$0.81+2.53%

Trading Information

  • Market Cap$43.73M
  • Float35.23%
  • Average Daily Volume (1m)194,238
  • Average Daily Volume (3m)186,344
  • EPS-$1.23

Company

  • Revenue$3.80M
  • Rev Growth (1yr)513.84%
  • Net Income-$11.01M
  • Gross Margin-88.83%
  • EBITDA Margin-1,123.26%
  • EBITDA-$10.96M
  • EV$84.77M
  • EV/Revenue22.31
  • P/EN/A
  • P/S10.28
  • P/BN/A